stockrow
Saturday 7 November 2026
Export GENB’s income statement to Excel — free account
Generate Biomedicines, Inc.
GENB Healthcare Biotechnology
Generate Biomedicines, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.9 million, up 55.9% from fiscal 2024.
13.06
0.49
+3.90%
Follow GENB
Alert me
| Dec '24 | Dec '25 | |
|---|---|---|
P/E ratio |
0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 |
P/FCF ratio |
0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(1.95) | (9.12) |
P/Operating CF |
(2.08) | (2.08) |
P/B ratio |
0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 |
EV/Operating CF |
(0.47) | (0.47) |
EV/FCF |
(0.46) | (0.46) |
Quick Ratio |
4.56 | 2.70 |
Current Ratio |
4.70 | 2.85 |
Net Debt/EBITDA |
2.08 | 0.97 |
Debt/Assets |
1.24% | 0.88% |
Debt/Equity |
(0.01) | 0.00 |
Asset Turnover |
0.00 | 0.08 |
Operating CF/Net income |
0.55 | 0.80 |
Capex/Depreciation |
(0.35) | (0.34) |
Interest Coverage |
(92.98) | (206.92) |
| 0.00% | 47.51% | |
| 0.00% | (58.82%) | |
ROIC |
0.00% | 0.00% |
Return on Tangible Assets |
(59.62%) | (137.62%) |
Average Days of Receivables |
5.49 | 0.00 |
Research and Development Expense of Revenue |
856.89% | 704.54% |
Selling, General and Administrative Expense of Revenue |
205.71% | 132.51% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
95.14% | 64.52% |
Graham Net Nets |
(1.71) | (1.71) |
Graham Number |
0.00 | 0.00 |
Earnings Yield |
(30.53%) | (30.53%) |
Free Cash Flow Yield |
(102.57%) | (102.57%) |
Revenue per Share |
0.64 | 0.97 |
Operating CF per Share |
(3.67) | (6.08) |
Capex per Share |
(0.11) | (0.11) |
Free Cash Flow per Share |
(3.78) | (6.19) |
Cash per Share |
12.31 | 6.73 |
Shareholders Equity per Share |
(13.54) | (18.68) |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
(13.54) | (18.68) |
Free Cash Flow |
(121.19) | (204.13) |
Working Capital |
320.87 | 152.16 |
Capital Expenditures |
(3.44) | (3.51) |
Net Current Asset Value |
(545.29) | (711.78) |
EV/EBIT |
0.00 | 0.00 |
Capex to Sales |
0.17 | 0.11 |
Price to Operating Income |
0.00 | 0.00 |
| Other line items | ||
Depreciation/Fixed assets |
0.26 | 0.36 |
Cash ROIC |
367.03% | 52.18% |
Accounts Receivable Turnover |
0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 |
Average Days of Payables |
0.00 | 0.00 |
Average Payables |
— | 4.75 |
Average Assets |
— | 424.22 |
Average Common Equity |
— | (525.24) |
Columns are period end dates · fundamentals updated 26 Oct 2026